{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:27:22Z","timestamp":1793816842260,"version":"4.6.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.antiviral.2019.06.005","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:04:34Z","timestamp":1559937874000},"page":"168-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["The development and approval of tecoviromat (TPOXX\u00ae), the first antiviral against smallpox"],"prefix":"10.1016","volume":"168","author":[{"given":"Michael","family":"Merchlinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Albright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Schiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Merkeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claiborne","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Challberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.06.005_bib1","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2019.06.005_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061514","article-title":"Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection","volume":"8","author":"Amantana","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.06.005_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1586\/14787210.2014.979157","article-title":"Discovery of forgotten variola specimens at the National Institutes of Health in the USA","volume":"12","author":"Arita","year":"2014","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"10.1016\/j.antiviral.2019.06.005_bib4","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00678-09","article-title":"Infection ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation Antimicrob","volume":"53","author":"Berhanu","year":"2009","journal-title":"Agents Chemother"},{"key":"10.1016\/j.antiviral.2019.06.005_bib5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.meegid.2012.12.002","article-title":"A survey of host range genes in poxvirus genomes","volume":"14","author":"Bratke","year":"2013","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.antiviral.2019.06.005_bib6","first-page":"339","article-title":"Public Health Service recommendations on smallpox vaccination","volume":"20","author":"CDC","year":"1971","journal-title":"MMWR (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.antiviral.2019.06.005_bib7","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1128\/AAC.00904-12","article-title":"Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers","volume":"56","author":"Chinsangaram","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.06.005_bib8","series-title":"Pandemic and All-Hazards Preparedness Reauthorization Act 2013 Title IV S. 401-402 (USA)","author":"CR","year":"2013"},{"key":"10.1016\/j.antiviral.2019.06.005_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"issue":"105","key":"10.1016\/j.antiviral.2019.06.005_bib10","first-page":"37988","article-title":"New drug and biological drug products: evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not feasible or ethical Fed","volume":"67","author":"FDA","year":"2002","journal-title":"Register 2002"},{"key":"10.1016\/j.antiviral.2019.06.005_bib11","series-title":"U.S. Food and Drug Administration. Summary Minutes of the Antiviral Drugs Advisory Committee Meeting Held December 14-15 2011","author":"FDA","year":"2011"},{"key":"10.1016\/j.antiviral.2019.06.005_bib12","series-title":"Product Development under the Animal Rule Guidance for Industry","author":"FDA","year":"2015"},{"key":"10.1016\/j.antiviral.2019.06.005_bib13","series-title":"Home Page for EUA","author":"FDA","year":"2018"},{"key":"10.1016\/j.antiviral.2019.06.005_bib14","series-title":"Summary Minutes for the Anti-infective Drugs Advisory Committee Meeting, May 1, 2018","author":"FDA","year":"2018"},{"key":"10.1016\/j.antiviral.2019.06.005_bib15","series-title":"Smallpox and its Eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.antiviral.2019.06.005_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/v8070203","article-title":"Ectromelia virus disease characterization in the BALB,\/c mouse: a surrogate model for assessment of smallpox medical countermeasures","volume":"8","author":"Garver","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.06.005_bib17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1073\/pnas.0912134107","article-title":"Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice","volume":"107","author":"Grosenbach","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2019.06.005_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the Small-Molecule Antiviral ST-246 as a Smallpox Therapeutic","volume":"6","author":"Grosenbach","year":"2011","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2019.06.005_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.06.005_bib20","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.antiviral.2019.06.005_bib21","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.0405954101","article-title":"Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox","volume":"101","author":"Jahrling","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.06.005_bib22","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.06.005_bib23","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246 for treatment of poxvirus infections","volume":"2","author":"Jordan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.06.005_bib24","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/AAC.01689-09","article-title":"Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects","volume":"54","author":"Jordan","year":"2010","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.antiviral.2019.06.005_bib25","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1016\/j.vaccine.2013.08.039","article-title":"The effects of post-exposure smallpox vaccination on clinical disease presentation: addressing the data gaps between historical epidemiology and modern surrogate model data","volume":"31","author":"Keckler","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2019.06.005_bib26","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.00959-12","article-title":"Pharmacokinetic and pharmacodynamics modeling to determine the dose of ST-246 to protect against smallpox in humans","volume":"57","author":"Leeds","year":"2013","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.antiviral.2019.06.005_bib27","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/AAC.00977-13","article-title":"Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (smallpox)","volume":"57","author":"Mucker","year":"2013","journal-title":"Antimicrob. Agents Chemother"},{"issue":"1","key":"10.1016\/j.antiviral.2019.06.005_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188453","article-title":"Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments","volume":"13","author":"Noyce","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.06.005_bib29","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3390\/v2091918","article-title":"Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics","volume":"2","author":"Parker","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.06.005_bib30","first-page":"1","article-title":"Rabbitpox in New Zealand white rabbits: a therapeutic model for evaluation of poxvirus medical countermeasures under the FDA Animal Rule Fron","volume":"8","author":"Perry","year":"2018","journal-title":"In Cell. and Inf. Micro."},{"key":"10.1016\/j.antiviral.2019.06.005_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/AAC.01044-08","article-title":"In vitro efficacy of ST-246 against smallpox and monkeypox","volume":"53","author":"Smith","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.06.005_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024832","article-title":"Progression of pathogenic events in cynomolgus macaques infected with variola virus","volume":"6","author":"Wahl-Jensen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.06.005_bib33","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yuang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.06.005_bib34","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1128\/JVI.03426-12","article-title":"Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells","volume":"87","author":"Zaitseva","year":"2013","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219303213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219303213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:23Z","timestamp":1759062503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219303213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"alternative-id":["S0166354219303213"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.06.005","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The development and approval of tecoviromat (TPOXX\u00ae), the first antiviral against smallpox","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}